VERVE-101 and VERVE-102 are an experimental gene therapy developed by Verve Therapeutics that targets the PCSK9 gene and is intended to reduce blood cholesterol levels. It works on the same protein as the cholesterol-lowering drugs known as PCSK9 inhibitors but, unlike them, is permanent. It works via base editing, a form of CRISPR gene editing. It is one of the first gene therapies that could be beneficial to a wider segment of the population, in contrast to earlier gene therapies that were developed to treat a rare genetic disorder.[1][2][3][4][5] Both treatments use the same RNA gene editing technology, but they use a different lipid nanoparticle delivery vehicle.[6]
References
🔥 Top keywords: Main PageSpecial:SearchPage 3Wikipedia:Featured picturesHouse of the DragonUEFA Euro 2024Bryson DeChambeauJuneteenthInside Out 2Eid al-AdhaCleopatraDeaths in 2024Merrily We Roll Along (musical)Jonathan GroffJude Bellingham.xxx77th Tony AwardsBridgertonGary PlauchéKylian MbappéDaniel RadcliffeUEFA European Championship2024 ICC Men's T20 World CupUnit 731The Boys (TV series)Rory McIlroyN'Golo KantéUEFA Euro 2020YouTubeRomelu LukakuOpinion polling for the 2024 United Kingdom general electionThe Boys season 4Romania national football teamNicola CoughlanStereophonic (play)Gene WilderErin DarkeAntoine GriezmannProject 2025